Papp KA, et al. - Authors assessed whether ixekizumab, an approved psoriasis treatment, was better at improving psoriasis symptoms than placebo (a nonactive drug) or etanercept (another approved psoriasis treatment). Findings suggested that compared to placebo and etanercept, ixekizumab treatment was seen to be better, patients treated with ixekizumab started to do better as early as Week 1. During the first 12 weeks, ixekizumab given every 2 weeks was better than ixekizumab given every 4 weeks. A likelihood to have a good response for psoriasis was seen in patients who took ixekizumab.